| | Journal Article Introduction A. KNOX, A. SZCZEKLIK, and G. PATRIARCA Thorax. 2000 October; 55(Suppl 2): S1–S2. doi: 10.1136/thorax.55.suppl_2.S1.PMCID: PMC1765965 Aspirin and other anti-inflammatory drugs S. J. Vane Thorax. 2000 October; 55(Suppl 2): S3–S9. doi: 10.1136/thorax.55.suppl_2.S3.PMCID: PMC1765977 Aspirin triggered lipid mediators: novel inhibitors of leucocyte
trafficking C. Serhan and C. Clish Thorax. 2000 October; 55(Suppl 2): S10–S12. doi: 10.1136/thorax.55.suppl_2.S10.PMCID: PMC1765970 A new class of lipid mediators: cytochrome P450 arachidonate
metabolites M. Carroll and J. McGiff Thorax. 2000 October; 55(Suppl 2): S13–S16. doi: 10.1136/thorax.55.suppl_2.S13.PMCID: PMC1765956 Unusual effects of aspirin on ticlopidine induced
thrombolysis R Gryglewski, W Uracz, and J Swies Thorax. 2000 October; 55(Suppl 2): S17–S19. doi: 10.1136/thorax.55.suppl_2.S17.PMCID: PMC1765972 Epidemiology of chronic
rhinosinusitis P Van Cauwenberge and J Watelet Thorax. 2000 October; 55(Suppl 2): S20–S21. doi: 10.1136/thorax.55.suppl_2.S20.PMCID: PMC1765976 Perennial allergic rhinitis and
keratoconjunctivitis J Rihoux Thorax. 2000 October; 55(Suppl 2): S22–S23. doi: 10.1136/thorax.55.suppl_2.S22.PMCID: PMC1765957 Haemopoietic mechanisms in nasal polyposis and
asthma J. Denburg Thorax. 2000 October; 55(Suppl 2): S24–S25. doi: 10.1136/thorax.55.suppl_2.S24.PMCID: PMC1765961 United airways disease: therapeutic
aspects G. Passalacqua, G. Ciprandi, and G. W. Canonica Thorax. 2000 October; 55(Suppl 2): S26–S27. doi: 10.1136/thorax.55.suppl_2.S26.PMCID: PMC1765974 Variant LTC4 synthase allele modifies cysteinyl
leukotriene synthesis in eosinophils and predicts clinical response to
zafirlukast A Sampson, S Siddiqui, D Buchanan, P Howarth, S Holgate, J Holloway, and I Sayers Thorax. 2000 October; 55(Suppl 2): S28–S31. doi: 10.1136/thorax.55.suppl_2.S28.PMCID: PMC1765955 Role of leukotrienes in bronchial hyperresponsiveness and
cellular responses in airways A. Leff Thorax. 2000 October; 55(Suppl 2): S32–S37. doi: 10.1136/thorax.55.suppl_2.S32.PMCID: PMC1765960 Lipoxins and other arachidonate derived mediators in bronchial
asthma C Chavis, I Vachier, P Godard, J Bousquet, and P Chanez Thorax. 2000 October; 55(Suppl 2): S38–S41. doi: 10.1136/thorax.55.suppl_2.S38.PMCID: PMC1765959 Clinical features and diagnosis of aspirin induced asthma A. Szczeklik and E. Nizankowska Thorax. 2000 October; 55(Suppl 2): S42–S44. doi: 10.1136/thorax.55.suppl_2.S42.PMCID: PMC1765966 Genetics of aspirin induced asthma M. Sanak and A. Szczeklik Thorax. 2000 October; 55(Suppl 2): S45–S47. doi: 10.1136/thorax.55.suppl_2.S45.PMCID: PMC1765951 Inhaled transmembrane ion transport modulators and non-steroidal
anti-inflammatory drugs in asthma S Bianco, M Robuschi, A Vaghi, A Fumagalli, and P Sestini Thorax. 2000 October; 55(Suppl 2): S48–S50. doi: 10.1136/thorax.55.suppl_2.S48.PMCID: PMC1765962 Oxidant stress in asthma R. Dworski Thorax. 2000 October; 55(Suppl 2): S51–S53. doi: 10.1136/thorax.55.suppl_2.S51.PMCID: PMC1765968 The importance of COX-2 inhibition for aspirin induced
asthma A. Bennett Thorax. 2000 October; 55(Suppl 2): S54–S56. doi: 10.1136/thorax.55.suppl_2.S54.PMCID: PMC1765952 Chronic bronchial asthma from challenge to treatment:
epidemiology and social impact M. Neri and A. Spanevello Thorax. 2000 October; 55(Suppl 2): S57–S58. doi: 10.1136/thorax.55.suppl_2.S57.PMCID: PMC1765963 New evidence of inflammation in
asthma A. Vignola, R. Gagliardo, D. Guerrera, G. Chiappara, P. Chanez, J. Bousquet, and G. Bonsignore Thorax. 2000 October; 55(Suppl 2): S59–S60. doi: 10.1136/thorax.55.suppl_2.S59.PMCID: PMC1765975 Allergic reactions to drugs: involvement of T
cells W. Pichler and N. Yawalkar Thorax. 2000 October; 55(Suppl 2): S61–S65. doi: 10.1136/thorax.55.suppl_2.S61.PMCID: PMC1765971 The aspirin disease D Schiavino, E Nucera, A Milani, M Del Ninno, A Buonomo, J Sun, and G Patriarca Thorax. 2000 October; 55(Suppl 2): S66–S69. doi: 10.1136/thorax.55.suppl_2.S66.PMCID: PMC1765964 Aspirin induced adverse skin reactions: new pathophysiological
aspects B. Wedi and A. Kapp Thorax. 2000 October; 55(Suppl 2): S70–S71. doi: 10.1136/thorax.55.suppl_2.S70.PMCID: PMC1765973 Hypersensitivity to pyrazolones M. Levy Thorax. 2000 October; 55(Suppl 2): S72–S74. doi: 10.1136/thorax.55.suppl_2.S72.PMCID: PMC1765954 Effects of lysine-acetylsalicylate (LAS) treatment in nasal
polyposis: two controlled long term prospective follow up
studies E Nucera, D Schiavino, A Milani, M Del Ninno, C Misuraca, A Buonomo, C D'Ambrosio, G Paludetti, and G Patriarca Thorax. 2000 October; 55(Suppl 2): S75–S78. doi: 10.1136/thorax.55.suppl_2.S75.PMCID: PMC1765967 Nasal polyposis, eosinophil dominated inflammation, and
allergy N. Mygind, R. Dahl, and C. Bachert Thorax. 2000 October; 55(Suppl 2): S79–S83. doi: 10.1136/thorax.55.suppl_2.S79.PMCID: PMC1765958 Rhinosinusitis and nasal polyposis in aspirin sensitive and
aspirin tolerant patients: are they
different? M. Kowalski Thorax. 2000 October; 55(Suppl 2): S84–S86. doi: 10.1136/thorax.55.suppl_2.S84.PMCID: PMC1765969 Surgical treatment of nasal polyposis in patients with aspirin
intolerance W Hosemann Thorax. 2000 October; 55(Suppl 2): S87–S90. doi: 10.1136/thorax.55.suppl_2.S87.PMCID: PMC1765953 |